Screening for Nitrosamines in Pharmaceutical Products
Feb 24 2020 Read 3892 Times
Nitrosamine are carcinogenic compounds so need to be monitored to ensure unsafe levels are not found in consumer products. Due to unsafe levels being found in a number of pharmaceutical products the EMA (European Medicines Agency) is requiring pharmaceutical companies to complete and submit a risk assessment by 26th March. This means many pharmaceutical manufacturers will potentially need to screen their products for nitrosamine content.
The Ellutia 800 Series TEA is perfectly suited to nitrosamine detection thanks to is selectivity and sensitivity for Nitroso compounds. For testing of pharmaceutical drugs, The 800 Series TEA can be interfaced to a chemical stripping system that allows for rapid testing of ATNC (Apparent Total N-nitrosamine content). This quickly gives an accurate result for the total nitrosamine content of a sample showing both volatile and non-volatile components.
Any positive sample can then be further analysed by an 800 Series TEA interfaced to a GC where volatile nitrosamines such as NDMA (N-Nitrosodimethylamine) can be separated and quantified.
More information online
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Issue Articles - Review of China market shows real potential for lab companies - Biphenyl Modified Silica Stabilised by Bulky Substituents Laboratory Products - ChIP Kits for H...
View all digital editions
Sep 20 2020 Preveza, Greece
Sep 21 2020 Budapest, Hungary
Sep 22 2020 Moscow, Russia
Sep 29 2020 Utrecht, Holland
Oct 06 2020 Lagos, Nigeria